22:19 , Jun 19, 2019 |  BC Extra  |  Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

Catalent buys Italian facility from BMS  Catalent Inc. (NYSE:CTLT) will buy an Italian manufacturing facility from Bristol-Myers Squibb Co. (NYSE:BMY) for an undisclosed amount. Catalent will manufacture oral solid, biologics and sterile products at the...
00:02 , Jun 19, 2019 |  BC Extra  |  Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb  The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
18:37 , Apr 4, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...
22:14 , Oct 2, 2018 |  BC Extra  |  Company News

Management tracks: Synlogic, Trevena, Editas

Synlogic Inc. (NASDAQ:SYBX) promoted Aoife Brennan to president and CEO. She has held both positions on an interim basis since May, when former President and CEO Jose Carlos Gutiérrez-Ramos resigned. Brennan had been CMO of...
22:50 , Sep 28, 2018 |  BC Extra  |  Company News

Management tracks: Zai, Selecta

Zai Lab Ltd. (NASDAQ:ZLAB) hired Tao Fu as COO. Fu was EVP and chief commercial and business officer of Portola Pharmaceuticals Inc. (NASDAQ:PTLA) (see "Amid Launch Troubles, Portola Commercial Chief Fu Resigns" ). Prior to...
19:06 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

China advisory committee to review CASI's multiple myeloma therapy

CASI Pharmaceuticals Inc. (NASDAQ:CASI) said China's Expert Advisory Anti-Tumor (Oncology) Drugs Committee will meet to review an application for CASI's Evomela melphalan to treat multiple myeloma. China FDA's Center for Drug Evaluation told CASI the...
18:40 , Mar 23, 2018 |  BC Week In Review  |  Financial News

CASI raises $50M in private placement

Cancer company CASI Pharmaceuticals Inc. (NASDAQ:CASI) raised $50 million on March 20 in a private placement through the sale of 15.4 million shares and accompanying warrants to purchase an additional 6.2 million shares at a...
19:01 , Oct 27, 2017 |  BC Week In Review  |  Financial News

CASI raises $23.9M in registered direct offering

On Oct. 13, CASI Pharmaceuticals Inc. (NASDAQ:CASI) raised $23.9 million through the sale of 8 million units at $3 in a registered direct offering led by existing stakeholders. Each unit comprises a share and two-and-a-half...
20:31 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

CASI completes enrollment in Phase II of ENMD-2076 for TNBC

In April, CASI Pharmaceuticals Inc. (NASDAQ:CASI) completed enrollment of 41 patients in a Phase II trial of ENMD-2076 in previously treated patients with locally advanced or metastatic triple-negative breast cancer (TNBC). The open-label, U.S. trial...
19:18 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

CASI reports Phase II data for ENMD-2076 in clear cell ovarian cancer

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, CASI Pharmaceuticals Inc. (NASDAQ:CASI) reported data from 37 evaluable patients with recurrent clear cell ovarian cancer in a Phase II...